{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116782","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.217070+00:00","generated_at":"2026-05-30T02:01:14.937525+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eyenovia Q3 2024 net loss $7.9M; advances MicroPine Phase 3 and launches clobetasol","bullets":["Net loss of $7.9M ($0.11/share) vs $7.3M ($0.18/share) in Q3 2023; SG&A up 27% to $3.7M.","Cash & equivalents $7.2M at Sept 30, 2024; evaluating long-term financing options.","Phase 3 CHAPERONE (MicroPine) interim analysis planned this quarter; myopia market >$3B annually.","U.S. launch of clobetasol propionate 0.05% for post-surgical ocular inflammation/pain.","Mydcombi shipped to 230 new offices since April; appointed Andrew Jones as CFO; raised $10.7M net."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116782","json":"https://secwatch.observer/filing/0001104659-24-116782.json","markdown":"https://secwatch.observer/filing/0001104659-24-116782.md","text":"https://secwatch.observer/filing/0001104659-24-116782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924116782/0001104659-24-116782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924116782/tm2428070d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:01:14.937525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}